J Pharm Pharm Sci. 2021;24:62-70. doi: 10.18433/jpps31629.
Post-operative pain is a common type of acute pain that can require therapeutic intervention. Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to manage post-operative pain and help reduce or eliminate the use of opioids. Current pain management guidelines recommend administration of NSAIDs as first line therapy to all post-operative surgical patients, unless contraindicated, as one method to minimize opioid use.
This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by the author. Literature for controlled trials involving naproxen in a peri-procedural setting was included. Comprehensive meta-analyses and individual clinical trial reports were summarized.
Naproxen was shown to have significant efficacy in treating pain following different surgical interventions, eliminating, or reducing the use of rescue opioids in many trials. Importantly, naproxen did not demonstrate an increased rate of bleeding or other adverse events in this elevated-risk population.
As a generally safe and effective medication, clinical consideration should be given to naproxen when developing any comprehensive, patient-specific, pain management plan.
术后疼痛是一种常见的急性疼痛，可能需要治疗干预。非甾体抗炎药（NSAIDs）常用于治疗术后疼痛，有助于减少或消除阿片类药物的使用。目前的疼痛管理指南建议，除非有禁忌症，否则将 NSAIDs 作为一线治疗药物用于所有术后手术患者，这是减少阿片类药物使用的一种方法。
本文基于先前进行的研究，不包含作者进行的任何涉及围手术期使用萘普生的人体参与者或动物研究。纳入了涉及萘普生在围手术期的对照试验文献。总结了综合荟萃分析和个别临床试验报告。
萘普生在治疗不同手术干预后的疼痛方面具有显著疗效，在许多试验中消除或减少了对救援阿片类药物的使用。重要的是，在这种高风险人群中，萘普生并未显示出血或其他不良事件的发生率增加。
作为一种通常安全有效的药物，在制定任何全面的、针对特定患者的疼痛管理计划时，应考虑使用萘普生。
